3 weeks ago
Emcure Pharma Q1 Net Profit Up 36% to ₹292.49 Crore
This story is about Emcure Pharmaceuticals, a company that makes medicines.
The company shared how much money it made in the first three months of its financial year, called Q1.
Its profit grew a lot compared with the same time last year, going up by 36.2%.
The company also earned more from selling its medicines, with revenue up 22.8%.
Sales in other countries grew especially fast and now bring in more than half of the company's income.
Emcure spent more on making and selling its products, which often happens when a business grows.
It also invested in research and development, which helps create new medicines in the future.
The company's Chairman, Berjis Desai, is retiring after the next shareholder meeting, and Satish Mehta will take over.
A new Chief Operating Officer for Emcure was also appointed.
These changes show the company is growing and getting ready for new leadership.
Emcure Pharmaceuticals' consolidated net profit for Q1 FY27 rose 36.2% year-on-year to ₹292.49 crore from ₹214.79 crore.
Revenue from operations increased 22.8% to ₹2,580.45 crore, up from ₹2,100.54 crore in Q1 FY26.
International business grew 34.2% to ₹1,485.10 crore, accounting for 57.6% of consolidated revenue from operations.
Basic earnings per share for the quarter stood at ₹15.50, up from ₹10.92 in the same quarter last year.
Berjis Desai will retire as Chairman after the AGM, with Satish Mehta set to succeed him; Samit Mehta was appointed COO of Emcure and CEO of Gennova Biopharmaceuticals.
- Who
- Emcure Pharmaceuticals, an India-based pharmaceutical company headquartered in Mumbai, and its leadership including Berjis Desai, Satish Mehta and Samit Mehta.
- What
- Announced Q1 FY27 financial results showing a 36.2% rise in consolidated net profit and a 22.8% increase in revenue from operations.
- Where
- Mumbai, India, with business spanning domestic and international markets.
- When
- Quarter ended 30 June 2026 (Q1 FY27), with results announced on Thursday.
- Why
- Profit growth was driven by strong performance, including a 34.2% increase in international business.
Key facts
- Net Profit
- ₹292.49 crore (up 36.2% year-on-year)
- Revenue from Operations
- ₹2,580.45 crore (up 22.8%)
- Total Income
- ₹2,582.52 crore
- Profit Before Tax
- ₹393.53 crore
- Basic EPS
- ₹15.50
- International Business Share
- 57.6% of revenue, growing 34.2%
- R&D Investment
- ₹90.40 crore (3.5% of revenue)
- Leadership Change
- Berjis Desai to retire; Satish Mehta to become Chairman








